Human C-Reactive Protein Binds Activating Fcγ Receptors and Protects Myeloma Tumor Cells from Apoptosis

Jing Yang, Michele Wezeman, Xiang Zhang, Pei Lin, Michael Wang, Jianfei Qian, Bo Wan, Larry W. Kwak, Long Yu, Qing Yi

Research output: Contribution to journalArticle

87 Scopus citations

Abstract

Elevated levels of C-reactive protein (CRP) are present in many disease situations including malignancies and may contribute to the pathogenesis of cardiovascular disorders. This study was undertaken in a myeloma setting to determine whether CRP affects tumor cell growth and survival. We show that CRP enhanced myeloma cell proliferation under stressed conditions and protected myeloma cells from chemotherapy drug-induced apoptosis in vitro and in vivo. CRP binds activating Fcγ receptors; activates PI3K/Akt, ERK, and NF-κB pathways; and inhibits caspase cascade activation induced by chemotherapy drugs. CRP also enhanced myeloma cell secretion of IL-6 and synergized with IL-6 to protect myeloma cells from chemotherapy drug-induced apoptosis. Thus, our results implicate CRP as a potential target for cancer treatment.

Original languageEnglish (US)
Pages (from-to)252-265
Number of pages14
JournalCancer Cell
Volume12
Issue number3
DOIs
StatePublished - Sep 11 2007

Keywords

  • CELLCYCLE

ASJC Scopus subject areas

  • Oncology
  • Cell Biology
  • Cancer Research

Fingerprint Dive into the research topics of 'Human C-Reactive Protein Binds Activating Fcγ Receptors and Protects Myeloma Tumor Cells from Apoptosis'. Together they form a unique fingerprint.

Cite this